These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

742 related items for PubMed ID: 8462317

  • 1. Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol.
    Hammerstein J, Daume E, Simon A, Winkler UH, Schindler AE, Back DJ, Ward S, Neiss A.
    Contraception; 1993 Mar; 47(3):263-81. PubMed ID: 8462317
    [Abstract] [Full Text] [Related]

  • 2. Group comparison of serum ethinyl estradiol, SHBG and CBG levels in 83 women using two low-dose combination oral contraceptives for three months.
    Dibbelt L, Knuppen R, Jütting G, Heimann S, Klipping CO, Parikka-Olexik H.
    Contraception; 1991 Jan; 43(1):1-21. PubMed ID: 1825969
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum.
    Kuhnz W, Baumann A, Staks T, Dibbelt L, Knuppen R, Jütting G.
    Contraception; 1993 Oct; 48(4):303-22. PubMed ID: 8222659
    [Abstract] [Full Text] [Related]

  • 4. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance.
    Endrikat J, Müller U, Düsterberg B.
    Contraception; 1997 Mar; 55(3):131-7. PubMed ID: 9115000
    [Abstract] [Full Text] [Related]

  • 5. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
    Crook D, Godsland IF, Worthington M, Felton CV, Proudler AJ, Stevenson JC.
    Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
    [Abstract] [Full Text] [Related]

  • 6. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins.
    Wiegratz I, Jung-Hoffmann C, Kuhl H.
    Contraception; 1995 Jun; 51(6):341-6. PubMed ID: 7554973
    [Abstract] [Full Text] [Related]

  • 7. Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters.
    Jung-Hoffmann C, Fitzner M, Kuhl H.
    Horm Res; 1991 Jun; 36(5-6):238-46. PubMed ID: 1823082
    [Abstract] [Full Text] [Related]

  • 8. Sex hormone binding globulin, cortisol binding globulin, thyroxine binding globulin, ceruloplasmin: changes in treatment with two oral contraceptives low in oestrogen.
    Sobbrio GA, Granata A, Granese D, D'Arrigo F, Panacea A, Nicita R, Pullè C, Trimarchi F.
    Clin Exp Obstet Gynecol; 1991 Jun; 18(1):43-5. PubMed ID: 1829029
    [Abstract] [Full Text] [Related]

  • 9. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
    Norris LA, Bonnar J.
    Br J Obstet Gynaecol; 1996 Mar; 103(3):261-7. PubMed ID: 8630312
    [Abstract] [Full Text] [Related]

  • 10. Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel.
    Hammond GL, Langley MS, Robinson PA, Nummi S, Lund L.
    Fertil Steril; 1984 Jul; 42(1):44-51. PubMed ID: 6233179
    [Abstract] [Full Text] [Related]

  • 11. Changes in androgens during treatment with four low-dose contraceptives.
    Coenen CM, Thomas CM, Borm GF, Hollanders JM, Rolland R.
    Contraception; 1996 Mar; 53(3):171-6. PubMed ID: 8689882
    [Abstract] [Full Text] [Related]

  • 12. Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women.
    Koetsawang S, Charoenvisal C, Banharnsupawat L, Singhakovin S, Kaewsuk O, Punnahitanont S.
    Contraception; 1995 Apr; 51(4):225-9. PubMed ID: 7796587
    [Abstract] [Full Text] [Related]

  • 13. Protein binding of active ingredients and comparison of serum ethinyl estradiol, sex hormone-binding globulin, corticosteroid-binding globulin, and cortisol levels in women using a combination of gestodene/ethinyl estradiol (Femovan) or a combination of desogestrel/ethinyl estradiol (Marvelon) and single-dose ethinyl estradiol bioequivalence from both oral contraceptives.
    Hümpel M, Täuber U, Kuhnz W, Pfeffer M, Brill K, Heithecker R, Louton T, Steinberg B, Seifert W, Schütt B.
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):329-33. PubMed ID: 2142574
    [Abstract] [Full Text] [Related]

  • 14. The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel.
    Orme M, Back DJ, Ward S, Green S.
    Contraception; 1991 Apr; 43(4):305-16. PubMed ID: 1830266
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of a triphasic oral contraceptive containing desogestrel and ethinyl estradiol.
    Archer DF, Timmer CJ, Lammers P.
    Fertil Steril; 1994 Apr; 61(4):645-51. PubMed ID: 8150105
    [Abstract] [Full Text] [Related]

  • 16. Evidence that treatment with monophasic oral contraceptive formulations containing ethinylestradiol plus gestodene reduces bone resorption in young women.
    Paoletti AM, Orrù M, Floris S, Mannias M, Vacca AM, Ajossa S, Guerriero S, Melis GB.
    Contraception; 2000 Apr; 61(4):259-63. PubMed ID: 10899481
    [Abstract] [Full Text] [Related]

  • 17. Comparison of serum ethinyl estradiol, sex-hormone-binding globulin, corticoid-binding globulin and cortisol levels in women using two low-dose combined oral contraceptives.
    Hümpel M, Tüber U, Kuhnz W, Pfeffer M, Brill K, Heithecker R, Louton T, Steinberg B.
    Horm Res; 1990 Apr; 33(1):35-9. PubMed ID: 2142929
    [Abstract] [Full Text] [Related]

  • 18. Protein binding of the contraceptive steroids gestodene, 3-keto-desogestrel and ethinylestradiol in human serum.
    Kuhnz W, Pfeffer M, al-Yacoub G.
    J Steroid Biochem; 1990 Feb; 35(2):313-8. PubMed ID: 2308344
    [Abstract] [Full Text] [Related]

  • 19. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol.
    Akerlund M, Røde A, Westergaard J.
    Br J Obstet Gynaecol; 1993 Sep; 100(9):832-8. PubMed ID: 8218004
    [Abstract] [Full Text] [Related]

  • 20. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
    Elomaa K, Rolland R, Brosens I, Moorrees M, Deprest J, Tuominen J, Lähteenmäki P.
    Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.